title: Advantages of every-3-week dosing of erythropoietic agents to manage chemotherapy-induced anemia.
authors.affiliation: St. Louis Hematology Oncology, Specialists, Inc, St. Louis, Missouri 63117, USA. jclarknp@sbcglobal.net
authors.forename: Joan
authors.initials: J
authors.lastname: Clark
authors.forename: Alvin
authors.initials: A
authors.lastname: Schergen
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004921:Erythropoietin